SHOP APOTHEKE EUROPE continues its accelerated growth course. Consolidated revenues more than doubled to EUR 257 million during the first half of 2018.

^{NOT FOR RELEASE OR DISTRIBUTION IN THE USA, CANADA, AUSTRALIA OR JAPAN.}
 

SHOP APOTHEKE EUROPE continues its accelerated growth course.
Consolidated revenues more than doubled to EUR 257 million during the first half of 2018.
 

• Increase of over 120 % to ca. EUR 202 million in German core market.
• International revenues rose by 61% to around EUR 55 million.

Venlo, the Netherlands, July 10, 2018. SHOP APOTHEKE EUROPE N.V., Europe's leading online pharmacy, continued to post strong growth during the first half of 2018. According to preliminary calculations group revenues increased by +103% to more than EUR 257 million compared to EUR 127 million for the first half of last year.

Organic growth and the consolidation of Europa Apotheek, which the company had acquired last year, led to a significant revenue boost in Germany. As a result SHOP APOTHEKE EUROPE increased its half-year revenues in Continental Europe's largest online pharmacy market by more than 120% to EUR 202 million compared to the same period last year (first half 2017: EUR 92 million). SHOP APOTHEKE EUROPE also continues to grow strongly in its international markets - Austria, Belgium, France, Italy, Spain and the Netherlands. Revenues for the "International" segment rose by EUR 21 million, from EUR 34 million to EUR 55 million, which is equivalent to a growth rate of more than 61%.

SHOP APOTHEKE EUROPE will publish the full half-year report as planned on August 14, 2018.
 

ABOUT SHOP APOTHEKE EUROPE.

SHOP APOTHEKE EUROPE is the leading and fastest growing online pharmacy in Continental Europe. With the acquisition of Europa Apotheek Venlo in November 2017, SHOP APOTHEKE EUROPE significantly extended its European market leadership with an expanded product range for the whole family in the areas of OTC, beauty and care products as well as prescription drugs.

SHOP APOTHEKE EUROPE already operates online pharmacies in Germany, Austria, France, Belgium, Italy, Spain and the Netherlands. In Germany, the TÜV-certified shop-apotheke.com is the market leading. SHOP APOTHEKE EUROPE delivers a broad range of more than 100,000 original products to over 2.8 million active customers quickly and at attractive prices. In addition, SHOP APOTHEKE EUROPE provides comprehensive and consistent pharmaceutical services.

SHOP APOTHEKE EUROPE N.V. has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 13 October 2016.
 

MEDIA CONTACTS.

Trade and public media:
Sven Schirmer
Mobile: +49 152 28 50 63 61
Email: presse@shop-apotheke.com

Financial media:
Thomas Schnorrenberg
Mobile: +49 151 46 53 13 17
Email: presse@shop-apotheke.com

Investor Relations:
Dr. Ulrich Wandel
Telephone: +31 77 850 6117
Email: ulrich.wandel@shop-apotheke.com

DISCLAIMER.

This publication is an advertisement. This communication constitutes neither an offer to sell nor a solicitation to buy securities of Shop Apotheke Europe N.V. in any jurisdiction. This is not a securities prospectus. No public offering of any securities of Shop Apotheke Europe N.V. is being made. Statements contained herein may constitute "forward-looking statements." Forward-looking statements are generally identifiable by the use of the words "may", "will", "should", "plan", "expect", "anticipate", "estimate," "believe", "intend", "project", "goal" or "target" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are based on current expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Group's or its industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. You should not place undue reliance on forward-looking statements and the Group does not undertake publicly to update or revise any forward-looking statement that may be made herein, whether as a result of new information, future events or otherwise.